Rapport Therapeutics (RAPP) Cash from Investing Activities (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Cash from Investing Activities data on file, last reported at $37.9 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $37.9 million, up 80.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$170.6 million (down 59.13% YoY), and the FY2025 annual result was -$187.5 million, down 10.19% from the prior year.
• Cash from Investing Activities improved to $37.9 million in Q1 2026 per RAPP's latest filing, from -$174.3 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $37.9 million in Q1 2026 and troughed at -$174.3 million in Q4 2025.
• A 4-year average of -$36.2 million and a median of -$41.9 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities sank 101901.92% in 2024, then surged 150.16% in 2025.
• A 4-year view of Cash from Investing Activities shows it stood at -$78.7 million in 2023, then soared by 140.59% to $31.9 million in 2024, then sank by 645.96% to -$174.3 million in 2025, then surged by 121.76% to $37.9 million in 2026.
• Business Quant data shows RAPP's Cash from Investing Activities at $37.9 million in Q1 2026, -$174.3 million in Q4 2025, and -$56.8 million in Q3 2025.